Rat igg1 isotype control antibody

Anti-CTLA4 (UC-10) and anti- IL7 receptor α (IL7Rα, CD127) (clone A7R34) (23 (link)) antibodies for in vivo blocking experiments were purified from hybridoma cell culture. BDC2.5/NOD/Foxp3^FIR mice were intraperitoneally administered with anti-CTLA4 (UC-10) antibody or Hamster IgG control antibody (Rockland Immunochemicals, Gilbertsville, PA), at a dose of 30ug/g body weight on day 8 and day 11 after birth. The flow cytometry analyses were done at 3 weeks of age. For anti-IL7Rα antibody treatment, CTLA4RNAi/B6.H2^g7 mice were intraperitoneally administered with anti-IL7Rα (A7R34) antibody or Rat IgG1 isotype control antibody (BioXcell, West Lebanon, NH) at a dose of 25ug/g body weight beginning at 3–4 days of age, twice a week for 3 weeks. These mice were then monitored for diabetes occurrence every 2–3 days till diabetes onset, or for 6 weeks. For anti-IFNγ antibody treatment, CTLA4RNAi/B6.H2^g7 mice were intraperitoneally administered with anti-IFNγ (clone XMG1.2) antibody or Rat IgG isotype control antibody (BioXcell) at a dose of 25ug/g body weight beginning at 3–4 days of age, twice a week for 3 weeks. These mice were then monitored for diabetes occurrence every 2–3 days till diabetes onset, or for 6 weeks.